Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 4,744 | 634 | 4,064 |
| Samples | 1,453 | 255 | 1,179 |
| Peptides | 1,281 | 205 | 1,094 |
Function
LAMA3 · Laminin subunit alpha 3
The protein encoded by this gene belongs to the laminin family of secreted molecules. Laminins are heterotrimeric molecules that consist of alpha, beta, and gamma subunits that assemble through a coiled-coil domain. Laminins are essential for formation and function of the basement membrane and have additional functions in regulating cell migration and mechanical signal transduction. This gene encodes an alpha subunit and is responsive to several epithelial-mesenchymal regulators including keratinocyte growth factor, epidermal growth factor and insulin-like growth factor. Mutations in this gene have been identified as the cause of Herlitz type junctional epidermolysis bullosa and laryngoonychocutaneous syndrome. Alternative splicing and alternative promoter usage result in multiple transcript variants. [provided by RefSeq, Dec 2014].
Isoforms & Proteins
5 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000313654 | Q16787 | 1,741 | 1,252 |
| ENST00000399516 | Q16787-3 | 1,548 | 1,155 |
| ENST00000269217 | Q16787-1 | 741 | 582 |
| ENST00000587184 | Q16787-4 | 713 | 561 |
| ENST00000585600 | A0A075B783* | 1 | 1 |
Gene Properties
Recurrent Mutations
All 1252 amino-acid changes on canonical ENST00000313654 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in LAMA3 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in LAMA3 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 13/40 32% | 0/0 0% |
| Chronic Myelogenous Leukemia | 4/25 16% | 0/0 0% |
| Melanoma | 18/210 9% | 223/1899 12% |
| Endometrial Carcinoma | 16/42 38% | 52/612 8% |
| Hodgkins Lymphoma | 4/16 25% | 6/122 5% |
| Other Solid Cancers | 7/94 7% | 72/1515 5% |
| Non-Small Cell Lung Carcinoma | 21/304 7% | 60/1390 4% |
| Colorectal Carcinoma | 28/143 20% | 133/3239 4% |
| Bladder Carcinoma | 2/58 3% | 45/956 5% |
| Mesothelioma | 9/62 15% | 1/165 1% |
| Cervical Carcinoma | 5/35 14% | 14/422 3% |
| Gastric Carcinoma | 5/74 7% | 72/1809 4% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 5/133 4% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Acute Myeloid Leukemia | 3/90 3% | 0/0 0% |
| Neuroendocrine Tumour | 20/154 13% | 3/577 1% |
| Plasma Cell Myeloma | 6/44 14% | 5/305 2% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Squamous Cell Lung Carcinoma | 3/57 5% | 23/810 3% |
| Ovarian Carcinoma | 12/109 11% | 17/998 2% |
| Esophageal Squamous Cell Carcinoma | 4/51 8% | 63/2550 2% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Unknown | 0/10 0% | 1/29 3% |
| Other Sarcomas | 2/69 3% | 17/699 2% |
| Thyroid Gland Carcinoma | 4/45 9% | 36/1592 2% |
| Head and Neck Carcinoma | 4/85 5% | 33/1574 2% |
| Hepatocellular Carcinoma | 4/46 9% | 44/2210 2% |
| Glioma | 1/52 2% | 41/2127 2% |
| Retinoblastoma | 1/27 4% | 0/30 0% |
Mutation Distribution
Where LAMA3 is mutated · all tissues, split by cell line vs tissue
How many mutations in LAMA3 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 4,744 mutations in LAMA3
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|